Skip to content

Effectiveness evaluation of hypertonic dextrose therapy in knee osteoarthritis

Effects of Prolotherapy with Hypertonic Dextrose in Patients with Osteoarthritis of the Knee: A Randomized Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190921044831N2
Enrollment
80
Registered
2021-10-29
Start date
2021-09-23
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthrits. Primary generalized (osteo)arthritis

Interventions

Intervention 1: Intervention group: 80 patients with mild to moderate osteoarthritis of the knee aged 75-45 years for whom the diagnosis was made by physical examination and knee AP graphy according t
It is a muscle cramp

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: All patients with mild to moderate knee osteoarthritis aged 45-75 years according to Kellgren-Lawrence criteria and rheumatologist approval Absence of rheumatic diseases such as Rheumatoid Arthritis Pain and tenderness of the knee joint resistant to medicine and conservative therapy for 3 months

Exclusion criteria

Exclusion criteria: Pregnancy Medicine allergy to Oxycodone and Lidocaine 40kg/m2<BMI History of previous prolotherapy Loosening of ligaments and knee joint History of diabetes History of hematologic disease, especially with palpitations History of taking anticoagulants such as Plavix and warfarin History of joint injection in the last 3 months History of inflammatory joint disease and history of knee joint infection People who are candidates for knee surgery with grade 4 based on Kellgren-lawrence History of joint replacement and presence of joint prosthesis

Design outcomes

Primary

MeasureTime frame
Score of WOMAC questionnaire. Timepoint: 4, 8, 12, 16, 20, 24 weeks after injection. Method of measurement: Score of WOMAC questionnaire.

Secondary

MeasureTime frame
Clinical and functional status of the joint and persistence of the drug for 6 months after ending the treatment. Timepoint: 6 months after ending the treatment. Method of measurement: Questionnaire and clinical assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaasoomeh Salari

Mashhad University of Medical Sciences

Salarim@mums.ac.ir0538543031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026